Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT07096778 is registered in ClinicalTrials.gov with CellCentric Ltd. as lead sponsor.

NCT NCT07096778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07096778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
CellCentric Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
January 22, 2026
Completion date
December 1, 2029
Enrollment
100 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, multiple myeloma refractory